TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03188107

Intervention type: OTHER
Intervention: Video based assessment
Description: All the infants included in this study will be assessed with Infant Motor Profile based on video recording.

Intervention type: OTHER
Intervention: Video based assessment
Description: All the infants included in this study will be assessed with Infant Motor Profile based on video recording.
Study: NCT03074071

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hope Enhancement Workshop
Description: Participants in the workshops will be prompted and guided through exercises that help them get in touch with goals that are not explicitly related to cure of disease. These goals will include symptom relief and other personal and or professional objectives.
Study: NCT00183157

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Intervention
Description: One-third of the enrollees will receive an assessment, a brief motivational interview performed by a trained peer counselor, direct referrals to community-based resources for adolescents, and a 10-day follow-up phone call. All participants will be followed over time and re-screened to measure the impact of the initial brief intervention on their drinking and drug-taking. The key hypothesis is that individuals who receive the brief motivational interview in the emergency department setting will have lower rates of alcohol and illicit drug use and fewer health consequences over time.
Study: NCT02753803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin, Pioglitazone, Evogliptin+Pioglitazone
Description: Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone, Evogliptin, Evogliptin+Pioglitazone
Description: Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin, Evogliptin+Pioglitazone, Pioglitazone
Description: Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone, Evogliptin+Pioglitazone, Evogliptin
Description: Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD
Study: NCT00183157

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assessment and list of resources
Description: One-third will receive only the assessment and a list of community resources. All participants will be followed over time and re-screened to measure the impact of the initial brief intervention on their drinking and drug-taking. The key hypothesis is that individuals who receive the brief motivational interview in the emergency department setting will have lower rates of alcohol and illicit drug use and fewer health consequences over time.
Study: NCT02753803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin+Pioglitazone, Evogliptin, Pioglitazone
Description: Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin+Pioglitazone, Pioglitazone, Evogliptin
Description: Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD
Study: NCT04669808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: Dry powder for intra-and peri-lesional injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: Dry powder for intra-and peri-lesional injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: Dry powder for intra-and peri-lesional injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: Dry powder for intra-and peri-lesional injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: Dry powder for intra-and peri-lesional injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: Dry powder for intra-and peri-lesional injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: Dry powder for intra-and peri-lesional injection.
Study: NCT00499681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given once daily, 1500mg, for 2 weeks; Given once daily, 1500mg, for 14 weeks in Arm II

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given once daily, 1500mg, for 2 weeks; Given once daily, 1500mg, for 14 weeks in Arm II

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given once daily, 2.5mg, for 2 weeks; Given once daily, 2.5mg, for 14 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given once daily, 2.5mg, for 2 weeks; Given once daily, 2.5mg, for 14 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given once daily for 2 weeks
Study: NCT01999452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paleolithic diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paleolithic diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes diet
Study: NCT03530397

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI5752
Description: Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI5752
Description: Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel or Nab-Paclitaxel
Description: Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
Study: NCT03385655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: 250mg, may dose escalate to 300mg if no drug-related GI tox in cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: 600mg once daily, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: 600mg twice daily, orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFI-400945
Description: Dose level assigned at enrollment, starting at 32mg/day on Days 1-7 and 15-21 or 15-28 depending on toxicity experienced.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: 400mg daily 3 weeks on, 1 week off

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab and Tremelimumab
Description: Durvalumab 1500mg day 1 every 4 weeks; Tremelimumab 225mg day 1 cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 IV 60min Day 1 q 21 days
Study: NCT03246789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engage-M
Description: Engage is a stepped care psychotherapy based on what is known about how older adults respond to depression interventions. Stepped care is a model of treatment that starts with the minimum effective therapeutic techniques first, and then based on how well people respond to treatment, additional therapeutic techniques are added until people are recovered from their depression.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness in Mind and Body
Description: An active intervention focusing on psychoeducation and de-stigmatization of health and mental health conditions. These sessions are commonly part of senior centers programs. W-MH will offer mental health referral to a clinic or primary care physician as part of senior center procedures for clients with positive PHQ-9s.
Study: NCT03693521

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Handgrip strength measurement
Description: Measurement of handgrip strength with Jamar hand-held dynamometer as a complement to standard care of patients with diabetes type 2 by diabetes-nurses.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care of patients with diabetes type 2 by diabetes-nurses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard care of patients with diabetes type 2 by diabetes-nurses.
Study: NCT01527123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2585823
Description: CLDM1%/BPO3%
Study: NCT02203877

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus fermentum CECT5716
Description: Intervention with a probiotic strain in form of a daily capsule containing 3x109cfu/capsule.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Intervention with a daily capsule containing maltodextrin as placebo
Study: NCT01082250

Intervention type: DRUG
Group type: OTHER
Intervention: Lurasidone HCl
Description: 120mg dose. 3-way cross-over for 21 days

Intervention type: DRUG
Group type: OTHER
Intervention: Lurasidone HCl
Description: 120mg dose. 3-way cross-over for 21 days
Study: NCT01127243

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: day-case laparoscopic supracervical hysterectomy
Description: patients discharged home the same day of the operation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inpatient LSH
Description: patients discharged home the day after the operation
Study: NCT00945282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761
Description: GSK2248761 30 mg capsule once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Lopinavir 400 mg and ritonovir 100 mg every 12 hours for 28 days. Lopinavir/ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class. Kaletra is a trademark of Abbott Laboratories.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Lopinavir 400 mg and ritonovir 100 mg every 12 hours for 28 days. Lopinavir/ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class. Kaletra is a trademark of Abbott Laboratories.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAART
Description: Highly Active Antiretroviral therapy of the doctor's choice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAART
Description: Highly Active Antiretroviral therapy of the doctor's choice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a capsule with no drug in it.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a capsule with no drug in it.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2248761
Description: GSK2248761 10 mg -20 mg or 40 mg - 90 mg once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
Study: NCT03494920

Intervention type: OTHER
Group type: OTHER
Intervention: Direct endovascular clot retrieval
Description: Direct endovascular clot retrieval within 4.5 hours of stroke onset

Intervention type: OTHER
Group type: OTHER
Intervention: Bridging thrombolysis followed by ECR
Description: Bridging thrombolysis followed by ECR within 4.5 hours of stroke onset
Study: NCT04220346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tablet group
Description: Children in the Tablet group started to play the game with Tablet about 5-10 minutes before circumcision, and continued to play the game during the whole procedure.
Study: NCT02093793

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PRECISION SCS Adapted for High-Rate SCS
Description: Comparison of spinal cord stimulation parameters

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRECISION SCS Adapted for High-Rate SCS
Description: Comparison of spinal cord stimulation parameters
Study: NCT01474941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04620110 or Placebo
Description: Multiple oral doses of 5 mg PF-04620110 as a modified-release formulation or placebo once daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04620110 or Placebo
Description: Multiple oral doses of 5 mg PF-04620110 as a modified-release formulation or placebo twice daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04620110 or Placebo
Description: Repeat Arm 1 or Arm 2
Study: NCT01879683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LiRIS® 400 mg
Description: LiRIS® 400 mg is a drug-device combination product which is placed in the bladder during cystoscopy, remains in the bladder for up to 14 days gradually releasing lidocaine, and removed from the bladder via cystoscopy.
Study: NCT01964417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy after bowel cleansing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy after bowel cleansing
Study: NCT01368250

Intervention type: PROCEDURE
Intervention: Transcatheter Aortic Valve Implantation
Description: Minimal Invasive Implantation of a biological prosthesis in Aortic Position
Study: NCT01825187

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ULTRAPRO Mesh
Description: Patients who are randomized to this group will received ULTRAPRO Mesh for their hernia repair

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3DMAX
Description: Patients who are randomized to this group will receive 3DMAX mesh for their hernia repair

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation
Description: To evaluate the ease of use and time it takes residents to place and perform the surgery using these two different meshes.
Study: NCT02855034

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: Blood samples for dosage: copeptin and protein S100B
Study: NCT01225614

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilevel pressure ventilator
Description: Nocturnal home ventilation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilevel pressure ventilator
Description: Nocturnal home ventilation
Study: NCT02257034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taichi

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Dance
Study: NCT04538638

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesenteric sparing ileocolic resection
Description: Mesentery left in situ

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central mesenterectomy ileocolic resection
Description: Mesentery is taken up to the level of the ileocolic trunk
Study: NCT00003239

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa
Description: Daily by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Daily by subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine Mepesuccinate
Description: Homoharringtonine is administered by continuous infusion on days 1-5.
Study: NCT00752050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mentor Purified Toxin Botulinum Toxin Type A
Description: For Part II, subjects in this arm will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 30 U of the Active Comparator Mentor Purified Toxin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Preservative-free Saline
Description: For Part II, subjects in this arm will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 0.5 mL of the placebo (preservative-free saline).
Study: NCT03550612

Intervention type: DIAGNOSTIC_TEST
Intervention: magnetic resonant imaging,cranial ultrasound.
Description: Magnetic resonant image performed at term gestation neonate suffer of hypoxic ischemic encephalopathy and its results will be analysed in details and classified according to global score of magnetic resonant image injury.Cranial ultrasound results will be analysed regards (periventricular - interventricular haemorrhage-Ventricular size-basal ganglia, thalamus and cerebellum affection) and Doppler (peak systolic flow velocity-end diastolic peak flow velocity-mean velocity and resistance index).Cerebral bleeding will be diagnosed be cranial ultrasound and confirmed be standard magnetic resonant image in term equivalent age.

Intervention type: DIAGNOSTIC_TEST
Intervention: Amplitude integrated electroencephalogram
Description: Amplitude integrated electroencephalogram before and during cooling will be assessed and classified according to Hellstrom Westas et al 2006 and it will be compared with the results of cranial ultrasound and magnetic resonant imaging.~Neurodevelopment study at 12 and 14 month age using Bayley ɪɪɪ score will be compared with the results of cranial ultrasound,magnetic resonant imaging and Amplitude integrated electroencephalogram.
Study: NCT04951830

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI of TMJ

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI of TMJ
Study: NCT04272346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing for others
Description: Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 20 minutes per session. Topics covered in each session will vary and are related to common cancer-related themes (e.g., receiving a diagnosis, undergoing treatment, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 week apart, and participants will be instructed to write about their experience for the benefit of a newly-diagnosed cancer patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Processing + writing for others
Description: Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 20 minutes per session. Topics covered in each session will vary and are related to common cancer-related themes (e.g., receiving a diagnosis, undergoing treatment, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 week apart. For the first three writing sessions, participants will write their deepest thoughts and feelings regarding cancer diagnosis and treatment. In the final writing session, participants will be instructed to write about their experience for the benefit of a newly-diagnosed cancer patient.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Facts-only writing
Description: Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 20 minutes per session. Topics covered in each session will vary and are related to common cancer-related themes (e.g., receiving a diagnosis, undergoing treatment, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 week apart. Unlike the previous conditions, participants will not be instructed to write about their experience for the benefit of a newly-diagnosed cancer patient.
Study: NCT01623115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for alirocumab)
Description: Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid Modifying Therapy (LMT)
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipid Modifying Therapy (LMT)
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.